Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.
|Grade||Last Price||% Change||Price Change|
ACAD closed down 3.98 percent on Thursday, May 25, 2017, on 3 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Trend Table & Recent Alerts
|See historical ACAD trend table...|
|Date||Alert Name||Type||% Chg|
|May 25||Reversal New Lows Setup||Bearish Swing Setup||0.00%|
|May 25||Expansion Breakdown||Bearish Swing Setup||0.00%|
|May 23||1,2,3 Retracement Bearish||Bearish Swing Setup||-4.65%|
|May 23||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-4.65%|
|May 22||NR7||Range Contraction||-6.21%|
|May 19||Slingshot Bearish||Bearish Swing Setup||-5.67%|
|May 17||New Downtrend||Bearish||-2.92%|
|May 17||Lower Bollinger Band Walk||Other||-2.92%|
|May 16||Lower Bollinger Band Walk||Other||-7.50%|
|May 15||Lower Bollinger Band Walk||Other||-7.92%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACAD news...
|52 Week High||42.49|
|52 Week Low||20.68|
|200-Day Moving Average||31.3703|
|50-Day Moving Average||32.4298|
|20-Day Moving Average||29.9155|
|10-Day Moving Average||27.735|
|Average True Range||1.1561|
|Chandelier Exit (Long, 3 ATRs)||31.7517|
|Chandelier Exit (Short, 3 ATRs)||29.5183|
|Upper Bollinger Band||35.0622|
|Lower Bollinger Band||24.7688|
|Percent B (%b)||0.15|
|MACD Signal Line||-1.5098|